Progyny, Inc. (NASDAQ:PGNY) Sees Large Increase in Short Interest

Progyny, Inc. (NASDAQ:PGNY) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 5,150,473 shares, a growth of 28.3% from the February 12th total of 4,015,675 shares. Based on an average daily volume of 1,654,500 shares, the short-interest ratio is currently 3.1 days. Currently, 6.9% of the shares of the stock are sold short. Currently, 6.9% of the shares of the stock are sold short. Based on an average daily volume of 1,654,500 shares, the short-interest ratio is currently 3.1 days.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares in the company, valued at $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have sold 7,455 shares of company stock worth $129,515. Company insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Progyny

Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in Progyny in the fourth quarter valued at about $25,000. Federated Hermes Inc. raised its holdings in Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after purchasing an additional 819 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the last quarter. Versant Capital Management Inc lifted its position in Progyny by 61.8% during the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after purchasing an additional 894 shares during the period. Finally, Covestor Ltd lifted its position in Progyny by 164.9% during the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after purchasing an additional 1,624 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of NASDAQ PGNY traded down $0.08 during trading on Monday, reaching $17.42. The company had a trading volume of 1,367,468 shares, compared to its average volume of 1,615,575. Progyny has a 52 week low of $16.75 and a 52 week high of $28.75. The business’s 50 day moving average price is $22.30 and its 200-day moving average price is $22.74. The stock has a market cap of $1.43 billion, a PE ratio of 26.80, a PEG ratio of 1.17 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. Progyny’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. BTIG Research cut their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Progyny in a research report on Friday, March 6th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They issued an “overweight” rating and a $29.00 price objective for the company. Finally, Canaccord Genuity Group decreased their target price on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a report on Wednesday, March 11th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.45.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.